Clinical Trials in Lithuania

• A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised
  2022-501361-44-00 Phase III Adult patients of either gender with active moderate to seve… Dr. Reddy's Laboratories Limited
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown
  2022-502779-40-99 Phase III Primary prevention of atherosclerotic cardiovascular disease… Novartis Pharma AG
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 Phase III Ulcerative colitis Merck Sharp & Dohme LLC
• A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix … Pending
  2023-509255-14-01 Phase II Advanced prostate cancer Antev Limited; Antev Nordic AB
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 Phase III Immune system diseases Sanofi-Aventis Recherche & Developpement
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o… Pending
  2025-521632-12-00 Phase III Patients on Factor Xa inhibitor treatment needing an urgent … VarmX B.V.
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending
  2025-522471-28-00 Phase III psoriatic arthritis (PsA) MoonLake Immunotherapeutics AG
• Supporting weak immune system during autoimmune therapy: testing Panzyga to prevent infections Pending
  2025-522854-37-00 Phase III Prevention of a Major infection in patients with Hypogammagl… Octapharma Pharmazeutika Produktionsgesellschaft mbH
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 Phase III Non-active Secondary Progressive Multiple Sclerosis (SPMS) Zenas Biopharma (USA) LLC
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 Phase II Ulcerative colitis (Inflammatory Bowel Disease) Spyre Therapeutics Inc.
• A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting
  2025-524404-29-00 Phase II Ulcerative Colitis, Active Moderate Eli Lilly & Co.
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Recruiting
  2025-521038-27-00 Phase III Immune system diseases Sanofi-Aventis Recherche & Developpement
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 Phase III Chronic Spontaneous Urticaria Celldex Therapeutics Inc.
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Recruiting
  2024-519818-31-01 Phase III Endometrial Cancer Advanced, Recurrent, Metastatic, or Prima… Genmab A/S
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 Phase III Newly Diagnosed AML with an NPM1 mutation Syndax Pharmaceuticals Inc.
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting
  2024-518777-34-00 Phase III B7-H4-Selected Advanced/Metastatic Endometrial Cancer. AstraZeneca AB
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting
  2025-522767-15-00 Phase III Acute Myeloid Leukemia Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A study on the immune response and safety of an investigational chickenpox vaccine and a marketed measles, mumps and rubella vaccine when ad… Recruiting
  2024-518840-18-00 Phase III Varicella GlaxoSmithKline Biologicals
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-… Recruiting
  2025-520982-39-00 Phase III Philadelphia Chromosome Positive or ABL-class Philadelphia C… Universita Degli Studi Di Milano Bicocca
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 Phase III Major Depressive Disorder Neurocrine Biosciences Inc.
• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th… Recruiting
  2025-521055-23-00 Phase II/III Chronic Idiopathic thrombocytopenic purpura Argenx
• A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Co… Recruiting
  2024-520201-39-00 Phase II Moderately to Severely Active Ulcerative Colitis Odyssey Therapeutics Inc.
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 Phase III Bronchiectasis Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 Phase III Acute Myeloid Leukemia (AML) Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Showing 1–24 of 243 trials